SEC Filing Summary: Synta Pharmaceuticals Corp. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report, dated September 30, 2010, details a material definitive agreement entered into by Synta Pharmaceuticals Corp. (the "Company"). The filing discloses the execution of a Loan and Security Agreement with General Electric Capital Corporation (GECC) and MidCap Funding III, LLC. Note: The request metadata references "MADRIGAL PHARMACEUTICALS, INC.", but the filing text explicitly identifies the registrant as "SYNTA PHARMACEUTICALS CORP."
Key Financial Metrics and Debt Structure
- Loan Amount: $15,000,000 aggregate principal borrowed and funded on September 30, 2010.
- Interest Rate: Fixed annual rate equal to the greater of (i) Treasury Rate + 8.72% or (ii) 9.75%.
- Repayment Terms: Monthly interest payments commence November 1, 2010. Principal repayment occurs in 27 approximately equal monthly installments starting July 1, 2011.
- Maturity Date: All unpaid principal and accrued interest are due on September 1, 2013, or earlier upon default.
- Fees: A final payment fee of 3% of the original principal is due upon full repayment. Prepayment premiums apply (4% in year one, 2% in year two, 1% in year three).
- Use of Proceeds: Working capital, general corporate purposes, and payoff of outstanding obligations under a 2004 Master Lease Agreement with GECC.
Material Changes and Collateral
The Company has incurred a new direct financial obligation of $15 million. The loan is secured by a first priority lien on substantially all existing and after-acquired assets, excluding intellectual property (IP). However, if the Company fails to maintain certain cash ratios, the security interest automatically expands to include IP assets. Additionally, the Company has pledged 100% of the stock of Synta Securities Corp. and 65% of the stock of Synta Limited as collateral.
Covenants, Risks, and Contingencies
- Negative Covenants: Restrictions include prohibitions on mergers, change of control, incurring additional indebtedness (with a $4 million exception for equipment financing), paying dividends, and disposing of property.
- Events of Default: Include failure to make payments, breach of covenants, or defaults on other indebtedness. Default triggers acceleration of obligations and a penalty interest rate of 5% above the applicable rate (up to the maximum allowable by law).
- Liquidity Risk: The Company must maintain specific cash ratios to prevent the automatic inclusion of IP assets in the collateral package.
Investor Verification Checklist
- Verify the exact Treasury Rate used to calculate the final interest rate (Treasury Rate + 8.72% vs. 9.75% floor).
- Confirm the Company's current cash ratios to assess the risk of IP assets being pledged as collateral.
- Review the status of the 2004 Master Lease Agreement obligations being paid off with these proceeds.
- Assess the impact of the 3% final payment fee and potential prepayment penalties on the total cost of capital.
- Check for any subsequent filings regarding the Company's ability to meet the monthly principal payments starting July 2011.